Sofosbuvir and Ledipasvir Decreased Nephrotic Syndrome Caused by IgA Nephropathy with a Membranoproliferative Pattern of Injury in Hepatitis C Virus-induced Cirrhosis: a Case Report

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2022 May 16

PMID 35571427

Authors

Xiaohao Zhang

Jing Zhou

Canming Li

Jialing Rao

Yuanqing Li

Jun Zhang

Hui Peng

Affiliations

Soon will be listed here.

Abstract

Background: Immunoglobulin (Ig) A nephropathy (IgAN) with a membranoproliferative pattern of injury that manifests as nephrotic syndrome (NS) is rarely reported in hepatitis C virus (HCV)-induced cirrhosis. It is not known whether eradication of HCV by direct-acting antiviral (DAA) drugs can lead to remission of proteinuria and improve the long-term prognosis.

Case Description: We report the case of a 52-year-old woman with HCV cirrhosis for 10 years. She had undergone splenectomy and cholecystectomy due to complications of liver cirrhosis. The patient presented with NS and was diagnosed by kidney biopsy with IgAN with a membranoproliferative pattern of injury. Twelve-week sofosbuvir and ledipasvir therapy successfully eradicated HCV in this decompensated cirrhosis patient and resulted in partial remission of IgAN. The patient stayed in partial remission for 4 years and had her first relapse with deterioration of portal hypertension and suspected hepatic carcinoma despite a sustained HCV virologic response. We consider the IgAN in this case to be secondary to liver cirrhosis and HCV infection rather than a primary nephropathy. DAA drugs which have no direct reno-protective effect resulted in partial remission of IgAN because they eradicated HCV and improved the liver disorder.

Conclusions: Although relapse of IgAN could occur when liver cirrhosis deteriorates, DAA treatment may be considered an alternative for similar patients.

References

Gagnier J, Kienle G, Altman D, Moher D, Sox H, Riley D . The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2014; 2(5):38-43. PMC: 3833570. DOI: 10.7453/gahmj.2013.008. View

Borgia S, Dearden J, Yoshida E, Shafran S, Brown A, Ben-Ari Z . Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019; 71(4):660-665. DOI: 10.1016/j.jhep.2019.05.028. View

Zhao L, Peng L, Yang D, Chen S, Lan Z, Zhu X . Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy. Clin Immunol. 2020; 217:108483. DOI: 10.1016/j.clim.2020.108483. View

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

Cao Y, Zhang Y, Wang S, Zou W . Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. Nephrol Dial Transplant. 2009; 24(9):2745-51. DOI: 10.1093/ndt/gfp167. View

Andeen N, Jefferson J, Akilesh S, Alpers C, Bissonnette M, Finn L . IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury. Hum Pathol. 2018; 81:272-280. DOI: 10.1016/j.humpath.2018.06.031. View

Nakamoto Y, Iida H, Kobayashi K, Dohi K, Kida H, Hattori N . Hepatic glomerulonephritis. Characteristics of hepatic IgA glomerulonephritis as the major part. Virchows Arch A Pathol Anat Histol. 1981; 392(1):45-54. DOI: 10.1007/BF00430547. View

Adebajo C, Sathick I, Garovic V . 63-year-old man with chronic hepatitis C virus infection and proteinuria. Mayo Clin Proc. 2013; 88(9):e93-7. DOI: 10.1016/j.mayocp.2012.11.017. View

Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E . Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991; 34(12):1606-10. DOI: 10.1002/art.1780341221. View

10.

El-Serag H, Hampel H, Yeh C, Rabeneck L . Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002; 36(6):1439-45. DOI: 10.1053/jhep.2002.37191. View

11.

Hemminger J, Arole V, Ayoub I, Brodsky S, Nadasdy T, Satoskar A . Acute glomerulonephritis with large confluent IgA-dominant deposits associated with liver cirrhosis. PLoS One. 2018; 13(4):e0193274. PMC: 5892865. DOI: 10.1371/journal.pone.0193274. View

12.

van Marck E, Deelder A, Gigase P . Effect of partial portal vein ligation on immune glomerular deposits in Schistosoma mansoni-infected mice. Br J Exp Pathol. 1977; 58(4):412-7. PMC: 2041209. View

13.

McGrogan A, Franssen C, de Vries C . The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2010; 26(2):414-30. DOI: 10.1093/ndt/gfq665. View

14.

Ghabra N, Piraino B, Greenberg A, Banner B . Resolution of cirrhotic glomerulonephritis following successful liver transplantation. Clin Nephrol. 1991; 35(1):6-9. View

15.

Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y . Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015; 30(8):1315-21. PMC: 4513896. DOI: 10.1093/ndt/gfv221. View

16.

. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011). 2019; 8(3):91-165. PMC: 6336217. DOI: 10.1016/j.kisu.2018.06.001. View

17.

Park H, Chen C, Wang W, Henry L, Cook R, Nelson D . Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2017; 67(2):492-504. PMC: 5814730. DOI: 10.1002/hep.29505. View

18.

Dey A, Bhattacharya A, Majumdar A . Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013; 23(2):143-5. PMC: 3658295. DOI: 10.4103/0971-4065.109443. View